Concepedia

Author

Ken Bartizal

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

K Bartizal, K F Bartizal, K. BARTIZAL, K. Bartizal, K. F. BARTIZAL, K.F. Bartizal, KEN BARTIZAL, Ken Bartizal, Ken F. Bartizal

63

Publications

4.2K

Citations

31

H-Index

70

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Cidara Therapeutics (United States)United States Military AcademyArcturus Therapeutics (United States)University of Wisconsin–Madison
KB

About

Ken Bartizal is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, microbiology, and antimicrobial resistance.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

17

23

2.4K

2

Health Sciences

8

8

369

3

Natural Sciences

5

5

305

4

Engineering

1

1

336

5

Allergy

1

1

10

Ken Bartizal

×

44

Publications

4.2K

Citations

31

H-Index

YearCitations

Platensimycin is a selective FabF inhibitor with potent antibiotic properties

Jun Wang, S.M. Soisson, Katherine Young,

Nature

2006

809

Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors

Cameron Douglas, Joseph A. D'Ippolito, G.-J. Shei,

Antimicrobial Agents and Chemotherapy

1997

336

Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis

George K. Abruzzo, Amy Flattery, Christopher Gill,

Antimicrobial Agents and Chemotherapy

1997

244

Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests

Ana Espinel‐Ingroff, Charles W. Kish, Thomas M. Kerkering,

Journal of Clinical Microbiology

1992

244

Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts

Robert A. Fromtling, J N Galgiani, Michael A. Pfaller,

Antimicrobial Agents and Chemotherapy

1993

198

Anthrax lethal factor inhibition

Wesley L. Shoop, Y. XIONG, Judyann Wiltsie,

Proceedings of the National Academy of Sciences

2005

176

Efficacy of the Echinocandin Caspofungin against Disseminated Aspergillosis and Candidiasis in Cyclophosphamide-Induced Immunosuppressed Mice

George K. Abruzzo, Charles Gill, Amy Flattery,

Antimicrobial Agents and Chemotherapy

2000

170

Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies

Martha Kurtz, George K. Abruzzo, Amy Flattery,

Infection and Immunity

1996

137

Global Distribution and Outcomes for Candida Species Causing Invasive Candidiasis: Results from an International Randomized Double-Blind Study of Caspofungin Versus Amphotericin B for the Treatment of Invasive Candidiasis

Arnaldo Lopes Colombo, John R. Perfect, Mark J. DiNubile,

European Journal of Clinical Microbiology & Infectious Diseases

2003

127

Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin

Voon Ong, Grayson Hough, Michael Schlosser,

Antimicrobial Agents and Chemotherapy

2016

120

Page 1